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The antifungal “paradoxical effect” has been described as the reversal of growth inhibition at high doses of echi-
nocandins, most usually caspofungin. This microbiological effect appears to be a cellular compensatory re-
sponse to cell wall damage, resulting in alteration of cell wall content and structure as well as fungal
morphology and growth. In vitro studies demonstrate this reproducible effect in a certain percentage of fungal
isolates, but animal model and clinical studies are less consistent. The calcineurin and Hsp90 cell signaling path-
ways appear to play a major role in regulating these cellular and structural changes. Regardless of the clinical
relevance of this paradoxical growth effect, understanding the speciﬁc actions of echinocandins is paramount to
optimizing their use at either standard or higher dosing schemes, as well as developing future improvements in
our antifungal arsenal.
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Echinocandin antifungals play a vital role in the clinical
armamentarium against invasive fungal infections [1,
2]. This class of antifungals exerts concentration-
dependent effects through noncompetitive inhibition
of β-1,3-glucan synthase, leading to damaged fungal
cell walls. Due to the nontoxic nature of these agents,
many clinicians have attempted to utilize higher than
standard recommended doses, especially for difﬁcult-
to-treat infections. Although there seem to be few tox-
icity issues with this elevated dosing strategy, there are
potential microbiological concerns that could reduce
antifungal activity. These worries are relevant not only
for daily high-dose echinocandin use, but also for future
schemes that could employ pulse intermittent (eg,
once weekly) higher dosing. Understanding these im-
portant microbiological effects following high-dose
echinocandin use is crucial before newer dosing strate-
gies are adopted into clinical practice.
THE ANTIFUNGAL PARADOXICAL
EFFECT
In 1948, Harry Eagle ﬁrst described what was later
called the Eagle effect, whereby penicillin added to
media at ascending doses expectedly killed more bacte-
ria, but after increasing beyond a critical concentration
the number of bacteria would paradoxically increase,
revealing a decreased antibacterial effect at higher
drug concentrations [3]. This microbiological phe-
nomenon was ﬁrst extended to antifungals in a 1988
in vitro study comparing the echinocandin cilofungin
(LY121019; no longer available) against various Candi-
da albicans and Candida tropicalis isolates [4]. In that
report, higher doses of the echinocandin paradoxically
led to reduced fungal killing. The authors describe that
“. . . a paradoxical effect was noted with cilofungin, in
that the inhibitory effect observed at lower concentra-
tions was followed by growth at higher concentrations
often equivalent to that in the growth control well.” A
study the next year found that 58% of C. albicans
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isolates and 27% of C. tropicalis isolates demonstrated the Eagle
effect at higher concentrations of cilofungin [5].
Although this phenomenon was subsequently mentioned in
the literature [6, 7], the seminal paper describing this microbio-
logical ﬁnding in detail was not published until 2004, where the
authors outlined resistance to growth inhibition and killing
among various clinical Candida isolates following exposure to
high concentrations of caspofungin [8]. This “paradoxical effect”
occurred in 16% (4/25) of C. albicans clinical isolates initially
tested, and then in 18% (3/17) in another group of isolates exam-
ined; in each strain with the paradoxical effect it was consistently
reproducible. These isolates all displayed caspofungin mean in-
hibitory concentrations (MICs) that were considered highly sus-
ceptible by routine in vitro testing (0.025–0.09 µg/mL), and
therefore the suggestion of growth inhibition might not have
been detected using only conventional approaches. Additional
Candida isolates originally without the paradoxical effect were re-
tested at much higher concentrations (up to 50 µg/mL) and did
not develop this condition even at these super-therapeutic levels.
However, whereas 52% of those isolates showed nonvisible
growth at higher caspofungin concentrations, they possessed a
small number of viable colonies on subculture testing, a term
coined the “mini-paradoxical effect.” This complex dynamic re-
lationship was postulated to be quadriphasic: There was growth
below the caspofungin MIC, growth inhibition above the caspo-
fungin MIC for several dilutions, release of growth inhibition at
higher caspofungin concentrations in those isolates with the par-
adoxical growth, and ﬁnally growth inhibition again at the high-
est caspofungin concentrations [8].
Subculture of these paradoxical isolates did not demonstrate
progeny colonies with total resistance, but instead yielded the
reproducible paradoxical effect of the parent strain. This sug-
gested that this paradoxical phenomenon was not due to
selection of a truly resistant subpopulation. Evaluation of caspo-
fungin concentration in the testing wells revealed no destruction
of the drug at these higher concentrations to explain the lack of
an inhibitory effect [8], ruling out the possibility of drug inac-
tivity as a source for the unexpected growth.
Several additional possibilities were explored related to the
mechanism of this paradoxical effect. Most Candida strains test-
ed were isolated well before echinocandins were introduced into
clinical use, so the emergence of this as a consequence of drug
use is not supported. The possibility of this paradoxical effect
being due to the physical aggregated state of the drug seems
less likely, as that would not explain the effect in some isolates
and not in others, nor the growth suppression at very high con-
centrations and the persistence of most of the caspofungin in
active form at the end of incubation [8].
In subsequently examining 17 Candida isolates, both sus-
ceptible and resistant to azoles, the caspofungin paradoxical ef-
fect was seen in 18% (3/17) of isolates, and revealed was no
correlation between genetically known azole resistance mecha-
nisms and the paradoxical effect phenotype [9]. Similarly, se-
quencing of mutations in known resistance-associated areas of
the gene encoding the target of the echinocandins, β-1,3-glucan
synthase (FKS1), showed no correlation. Glucan synthase enzy-
matic assays also revealed no upregulation of glucan synthase
activity in the cells demonstrating paradoxical growth.
Brief exposures to caspofungin eliminated the paradoxical ef-
fect with caspofungin (8 µg/mL) on C. albicans, yet sustained a
long postantifungal effect [10]. It is possible that this short ex-
posure to drug was sufﬁcient to inhibit the target enzyme, and
that prolonged exposure at higher concentrations led to adap-
tive and compensatory responses that limit further killing and
promote growth. Paradoxical growth may also be affected by
other growth conditions, as 4 different Candida species all ex-
hibited paradoxical growth more frequently when grown in bi-
oﬁlm (80%) compared with planktonic cells (40%) [11]. This
preponderance of strains in bioﬁlm yielding a paradoxical effect
was reproduced in another study with C. albicans echinocan-
din-resistant strains due to FKS1 hotspot mutations [12].
The paradoxical effect has been demonstrated in Aspergillus
species as well. The in vitro concentration-dependent effects of
each echinocandin against germinated and nongerminated As-
pergillus fumigatus, Aspergillus terreus, and Aspergillus ﬂavus
conidia revealed paradoxical increases in metabolic activity at
higher concentrations [13], and each of the 3 echinocandins in-
creased metabolic activity by approximately the same percent-
age. Caspofungin triggered the greatest number of strains to
display paradoxical growth (12/27 isolates), followed by anidu-
lafungin (7/27 isolates) and micafungin (3/27 isolates). Addi-
tionally, the mean concentration that yielded paradoxical
growth was lowest for caspofungin (4.2 µg/mL), compared
with micafungin (11.1 µg/mL) and anidulafungin (10.8 µg/mL).
PARADOXICAL EFFECT INFLUENCE ON CELL
WALL BIOSYNTHESIS MECHANISM
As echinocandins speciﬁcally target cell wall β-1,3-glucan syn-
thesis, a mechanistic focus for the paradoxical effect has cen-
tered on detailed examination of fungal cell wall content for
evidence of compensatory upregulation of other cell wall com-
ponents. By examining the fractionated cell wall of a C. albicans
strain previously reported to produce the paradoxical effect
under both the presence and absence of high doses of caspofun-
gin, β-1,3-glucan and, interestingly, β-1,6-glucan, were de-
creased, whereas chitin content was signiﬁcantly elevated [14].
This suggested a likely mechanism for this microbiological phe-
nomenon, whereby caspofungin retains its β-1,3-glucan inhibi-
tion even at high concentrations so that the enzyme itself is not
the focus, but chitin synthesis upregulation was compensatory,
leading to increased overall fungal growth.
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Examining cell wall ultrastructure by both scanning and trans-
mission electron microscopy of 4 different Candida species re-
vealed that paradoxical growth cells displayed budding cells
without clear rings around constrictions between mother and
daughter cells, enlarged yeasts forming clumps, and the absence
of ﬁlamentation, all opposite control cells without high-dose cas-
pofungin exposure [15]. Transmission electron microscopy stud-
ies revealed morphological changes, including a thinner inner cell
wall with the predominance of a more electron-dense layer, as
well as an abnormal thickness of the septa between mother and
daughter cells with no clear septation between the cells [15]. Val-
idating the earlier report, this study also demonstrated a 4.0- to
6.6-fold increase in chitin content during the paradoxical effect.
Another study with C. albicans validated that paradoxical
growth is not due to drug degradation or instability, as media
from high caspofungin concentration wells, where the fungus
demonstrated paradoxical growth, also inhibited the growth of ad-
ditional strains [16]. Cells exhibiting paradoxical growth showed
the same enlarged size, abnormal septation, and the absence of
ﬁlamentation as reported earlier. As previously reported [14, 15,
17–19], chitin content increased following caspofungin exposure;
however, this study uncovered that 23% of dead cells following
caspofungin treatment also had increased chitin, suggesting that
this increase in chitin was not sufﬁcient to escape caspofungin
killing in all cells. β-1,3-glucan detection via ﬂuorescent antibody
revealed that cells exhibiting the paradoxical effect displayed
β-1,3-glucan along the cell wall, similar to heat-treated cells and
opposite control untreated cells where the β-1,3-glucan is isolated
to the inner cell wall and inaccessible on the cell surface.
The addition of 50% human serum eliminated the caspofun-
gin paradoxical effect at concentrations up to 64 µg/mL, and with
10% human sera the effect was shifted to requiring higher con-
centrations of caspofungin, suggesting a possible role for protein
binding or some other sera factor [17]. Combination with the
chitin synthesis inhibitor nikkomycin Z [17] eliminated paradox-
ical growth. Additionally, the paradoxical effect was eliminated in
C. albicans irs4 and inp51 mutants, which lack phosphatidylino-
sitol-(4,5)-bisphosphate 5′-phosphatase, and the paradoxical
effect was reestablished in the reintegration strains. This is likely
due to regulation of the Mkc1–cell wall integrity pathway, which
targets chitin synthase and other cell wall stress responses [17].
In another study, nikkomycin Z, combined with caspofungin,
also eliminated the paradoxical effect of various Candida species
[20], even when used at sub-MIC concentrations.
CANDIDA SPECIES–SPECIFIC AND
ECHINOCANDIN-SPECIFIC FINDINGS
The paradoxical effect has been demonstrated in approximately
15%–30% of Candida isolates tested in numerous studies. To
evaluate echinocandin speciﬁcity surrounding the paradoxical
effect, a total of 60 isolates were tested against both micafungin
and anidulafungin, and no paradoxical or mini-paradoxical
effect was seen against those 2 echinocandins [8].
One analysis of isolates from cancer patients found a much
greater percentage of isolates displaying the paradoxical effect
than previously reported, including 90% of 20 C. albicans iso-
lates with caspofungin [21]. Only 2 species, C. tropicalis (7 of 10
isolates) and Candida krusei (6 of 10 isolates), showed a para-
doxical effect with micafungin. Anidulafungin triggered the
paradoxical effect in only 40% of C. albicans isolates and only
20% of C. tropicalis isolates. Candida glabrata did not have the
paradoxical effect with any of the 3 echinocandins.
Another study of 101 isolates of C. albicans found 14% with
paradoxical growth to caspofungin [22]. However, in that study
there was no paradoxical effect with micafungin nor with ani-
dulafungin. Interestingly, against Candida dubliniensis, the par-
adoxical effect following caspofungin exposure was seen in 90%
of 124 isolates, and micafungin induced the effect in 63% of 126
isolates. Another study found 38% of C. albicans strains with
paradoxical effect [16], highlighting the reproducible nature
of the paradoxical effect, yet no uniformly consistent incidence.
One particular fungal genotype does not seem to predispose
to the paradoxical effect. Multilocus microsatellite genotyping
found a high genetic diversity in C. albicans isolates with the
paradoxical effect, and therefore could not predict the paradox-
ical effect phenotype, suggesting it was not the result of some
inheritable trait among strains [23]. Similarly, examination of
37 A. ﬂavus isolates collected from 14 patients with invasive as-
pergillosis found that 6 (16%) had paradoxical growth following
caspofungin exposure [24]. However, the paradoxical growth
phenotype was again independent of microsatellite genotype.
PARADOXICAL EFFECT WITH ANIMAL MODEL
DATA
The in vitro microbiologic effect has been repeatedly seen, and
the cellular mechanism explored, but the real test is if the effect
carries over to animal models and, ultimately, to infected pa-
tients. One of the ﬁrst animal model studies tested 4 C. albicans
isolates that displayed the paradoxical effect and 1 isolate that
did not in a murine model of invasive candidiasis [25]. This ex-
amination was predicated on previous observations from mul-
tiple investigators that there was a perceived lack of caspofungin
dose-responsiveness above a certain dose [26, 27]. In this mu-
rine candidiasis study, there was a ﬂat dose response above
0.5 mg/kg of caspofungin, but there was not a consistently dem-
onstrated paradoxical effect in vivo by either survival or kidney
colony forming unit recovery [25]. It is of course conceivable
that the plateau response could be attributed to caspofungin
pharmacodynamics and is not necessarily a possible in vivo par-
adoxical effect.
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A C. albicans strain, after growth in the presence of high-dose
caspofungin, was infected in the wax moth larvae Galleria mello-
nella and showed approximately 40% less virulence compared
withC. albicans not previously exposed to high-dose caspofungin
[16].Additionally, those larvae infected with high-dose caspofun-
gin-exposed cells developed rapid melanization, conﬁrmed by
histopathology with melanotic capsules and a signiﬁcantly de-
creased number of hyphae in tissue. Study of those cells exposed
to high-dose caspofungin revealed a greater proinﬂammatory re-
sponse of tumor necrosis factor–α, interleukin 17, interleukin 12,
and interferon-γ when exposed to primary murine peritoneal
macrophages [16]. However, in a separate Drosophila model of
candidiasis, C. albicans and C. tropicalis strains, with and without
the paradoxical effect, showed no difference in virulence [28].
The ﬁrst mention of the paradoxical effect in Aspergillus spe-
cies was in a rabbit model of invasive aspergillosis [29] with no
decrease in survival at higher caspofungin dosing. In another
murine model of invasive aspergillosis [30], caspofungin and
micafungin each exhibited dose-dependent pharmacodynamic
activity and reduction in fungal burden, but caspofungin had a
steeper dose-response curve and a modest (P = .35) paradoxical
increase in fungal burden that was not seen inmicafungin-treated
animals. In 3 subsequent and different murine models of invasive
aspergillosis utilizing escalating doses of caspofungin, therapeutic
efﬁcacy was dose-dependent at 0.1 mg/kg/day and 1 mg/kg/day,
but there was a paradoxical increase in pulmonary fungal burden
and inﬂammation at 5 mg/kg/day [31]. Additionally, at the high-
er caspofungin dose, A. fumigatusmorphology appeared compa-
rable to untreated controls vs the impaired hyphae evident at
lower caspofungin doses. Immunologically, the higher dose of
caspofungin resulted in massive recruitment of neutrophils, com-
pared to the decreased recruitment and inﬂammatory pathology
seen with the lower doses. To evaluate a mechanism for the in-
ﬂammatory ﬁndings, an additional strain that did not exhibit the
paradoxical effect in vitro was infected in mice and those animals
treated with 5 mg/kg/day of caspofungin. The animals had the
noticeable proinﬂammatory response, which was therefore
thought to be unrelated to the paradoxical effect.
A dose-fractionation study of caspofungin (0.25, 1.0, and 4.0
mg/kg) divided into 3 different dosing intervals in a murine
model of invasive aspergillosis revealed concentration-dependent
reduction in mean pulmonary fungal burden in mice in the 1
mg/kg dosage group [32]. A paradoxical increase in fungal bur-
den was seen for each dosing interval in the highest (4 mg/kg)
dosage-fractionation group, yet survival rates did not differ sig-
niﬁcantly from those in the lower dosage-fractionation group.
A neutropenic murine model of disseminated C. glabrata in-
fection treated with a single dose of micafungin was more suc-
cessful in reducing fungal burden than smaller, more frequent
dosing schemes [33]. Therefore, no paradoxical effect was ob-
served with high micafungin doses. In a murine model of
mucormycosis due to Rhizopus oryzae, low-dose (0.5 mg/kg/
day), but not high-dose, caspofungin (2.5 or 5 mg/kg/day) im-
proved survival [34], suggesting the possibility of a paradoxical
effect for this organism.
PARADOXICAL EFFECT CLINICAL DATA
A multicenter, randomized, double-blind clinical trial of stan-
dard-dose caspofungin (50 mg/day) vs high-dose caspofungin
(150 mg/day) included 204 adult patients with invasive candi-
diasis [35]. Favorable responses were similar between the treat-
ment arms, and the high-dose regimen was well-tolerated,
suggesting no paradoxical effect in regards to efﬁcacy. A second
multicenter, randomized, double-blind clinical trial evaluated
micafungin at 2 doses (100 mg and 150 mg) vs caspofungin at
standard maintenance dosing (50 mg/day) and included 595
patients with invasive candidiasis [36]. Favorable responses
were again similar in all 3 echinocandin dosing groups, includ-
ing no differences in adverse events. This study noted a lower
than expected rate of success (53% vs 78%) among patients
with noncandidemic invasive infections in the higher-dose mi-
cafungin arm vs the lower-dose micafungin arm. It is possible
that the paradoxical effect played a role, as this clinical trial
was substantially larger than the earlier caspofungin trial, and
perhaps this larger sample size was able to detect this difference.
A retrospective analysis of 97 total patients with invasive
fungal infection from a single center included 63 patients who
received standard-dose caspofungin (50 mg/day) and 34 pa-
tients who received high-dose caspofungin (100 mg/day), each
combined with another antifungal for treatment [37].Multivar-
iate analysis showed no signiﬁcant differences in response be-
tween the treatment groups, and high-dose caspofungin was
well tolerated, suggesting no clinical impact of the higher
dose. An updated report from the same center on 91 patients
who received high-dose caspofungin showed again that the
dose was well tolerated [38]. In another study, 26 patients
who received high-dose micafungin (300 mg/day) were com-
pared to 58 patients who received standard-dose micafungin
(150 mg/day) in a retrospective review of adult patients with he-
matologic malignancies that demonstrated adverse events, and
outcomes were similar in each group [39]. There was no obvious
evidence of a paradoxical effect in the limited number of pa-
tients who had invasive fungal infections.
CALCINEURIN PLAYS KEY ROLES IN
PARADOXICAL GROWTH IN ASPERGILLUS
FUMIGATUS
Putative roles for calcineurin and protein kinase C in attenua-
tion of caspofungin activity at higher concentrations in C. albi-
cans were ﬁrst reported in 2005 [19, 40]. The in vitro positive
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interaction of caspofungin with calcineurin inhibitors (tacroli-
mus/FK506, cyclosporine/CsA) in A. fumigatus was then shown
to exacerbate the delayed ﬁlamentation caused by calcineurin
inhibition and also result in fungicidal activity [41]. Further-
more, the potential of calcineurin pathway inhibition without
the emergence of drug resistance was demonstrated by examin-
ing the in vitro antifungal activity of calcineurin inhibi-
tors against A. fumigatus clinical isolates [42]. In addition, the
direct role for calcineurin in the regulation of the caspofungin-
mediated paradoxical growth was demonstrated by deletion of
the gene encoding the catalytic subunit of calcineurin (cnaA)
[43, 44]. While the cell wall inhibitors caspofungin and nikko-
mycin Z exhibited enhanced morphological defects in the cnaA
deletion strain, the cnaA deletion strain also revealed decreased
β-1,3-glucan content of the cell wall, implicating calcineurin in-
hibition or mutation as an excellent adjunct therapeutic target
in combination with the anti–cell wall drugs [45].
Efforts to examine the calcineurin-mediated downstream
regulatory cascade important for cell wall biosynthesis identi-
ﬁed crzA, the fungal ortholog of mammalian NFAT, as the
key transcription factor involved in hyphal growth and disease
dissemination [46]. Both the A. fumigatus cnaA and the crzA
deletion strains exhibited defects in proper incorporation of chi-
tin and β-1,3-glucan, the major components of the cell wall
[47], and abolished caspofungin-mediated paradoxical growth
at higher concentrations [48]. Compensatory transcriptional
upregulation of chitin synthases and increased chitin content
following caspofungin treatment was also evident [48]. The in-
creased sensitivity of the A. fumigatus cnaA and crzA deletion
strains to caspofungin was not recapitulated with the cell mem-
brane–active antifungals amphotericin B and voriconazole,
conﬁrming that the observed effects are speciﬁc to echinocan-
din [48].
The molecular role for calcineurin in the activation of chitin
biosynthesis process under high-dose caspofungin treatment
was revealed by enhanced expression of 2 of the A. fumigatus
chitin synthase genes, chsA and chsC, leading to a calcineur-
in-dependent increase in chitin synthase activity [48], presum-
ably as a compensatory response to inhibition of β-1,3-glucan
synthesis. Deletion of A. fumigatus chsA and chsC indicated
that the calcineurin pathway may also play roles in the tran-
scriptional regulation of other gene subsets essential for survival
in the presence of caspofungin or involves a more complicated
posttranscriptional regulation of chitin synthesis [49]. Adding
to this complexity, a recent study deciphering the role of all
the 8 chitin synthase genes belonging to the 2 families, 1 and
2, indicated that even quadruple deletion of family 1 chitin syn-
thase genes did not affect chitin content, albeit with morpholog-
ical abnormalities [50].However, quadruple deletion of family 2
chitin synthase genes resulted in disorganized mycelial struc-
ture without any effect on chitin contents [50].
Although the exact underlying mechanism responsible for
the calcineurin-mediated paradoxical reversal of growth inhibi-
tion at high doses of caspofungin remains unknown, the data
available thus far indicate that the lack of paradoxical growth
seen in the calcineurin pathway mutants is an outcome directly
related to cell wall stress induced via caspofungin treatment and
calcineurin pathway mutation. Recent works indicated that cal-
cineurin may regulate key proteins involved in caspofungin-
mediated paradoxical growth through localization at the hyphal
tip and the hyphal septum and via its activation by phosphor-
ylation (Figure 1) [51]. Mutations in key domains of CnaA that
caused mislocalization of calcineurin from the hyphal septum
[52] also showed defects in caspofungin-mediated paradoxical
growth [53]. For the ﬁrst time, mass spectrometry revealed
the phosphorylation of CnaA at a ﬁlamentous fungal-speciﬁc
domain (designated as the serine-proline rich region [SPRR])
that is completely absent in human calcineurin, and mutation
of the phosphorylated residues within the SPRR completely
abolished paradoxical growth due to caspofungin [53].
Although the regulation of chitin synthases by Ca2+ and the
calcineurin pathway has only been explored in a few fungal spe-
cies, calmodulin, a key modulator of calcineurin, has been im-
plicated in the proper activation of chitin synthase activity in
Neurospora crassa [54]. In addition, in the dimorphic fungus
Benjaminiella poitrasii, upregulation of chitin synthase activity
can be attenuated by blocking Ca2+ channels [55]. Based on in
vitro data, calcineurin activity and calmodulin are important for
wild-type levels of chitin synthase activity in A. fumigatus [48].
This role likely involves the calmodulin-mediated activation of
CnaA in response to cell wall stress following caspofungin treat-
ment. Activated CnaA that is phosphorylated can subsequently
dephosphorylate its transcription factor, CrzA, which, in turn,
induces transcription of key cell wall–related genes encoding for
the chitin synthases and β-1,3-glucan synthase. These chitin
synthases also may be responsible for the chitin biosynthetic re-
sponse to β-1,3-glucan synthase inhibition. Although our data
support this model, we cannot rule out the possibility that cal-
cineurin may posttranslationally control other proteins impor-
tant for chitin biosynthesis, including the chitin synthases
themselves, via dephosphorylation. In fact, the increased chitin
content observed in the A. fumigatus ΔcrzAmutant at high cas-
pofungin concentrations supports the possibility of an alterna-
tive mechanism for CnaA function in chitin biosynthesis. A
deeper understanding of these mechanisms could lead to even
greater therapeutic beneﬁts from echinocandin treatment.
Undoubtedly, the use of calcineurin inhibitors in combina-
tion with cell wall inhibitors as treatment regimen is therefore
potentially attractive. Recently caspofungin-mediated paradox-
ical growth was also evident in 60% of Candida species isolated
from the bloodstream, which was eliminated by calcineurin
pathway inhibitors (tacrolimus and cyclosporine A), and the
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chitin synthase inhibitor, nikkomycin Z, with these inhibitors
also being synergistic with caspofungin [10].
HSP90 PATHWAY: EMERGING AS A KEY
REGULATOR OF PARADOXICAL GROWTH
As a molecular chaperone, heat shock protein 90 (Hsp90) controls
the maturation, folding, and activation of a major part of the
eukaryotic proteome, and assumes the role of guardian of intracel-
lular homeostasis by governing multiple networks of stress
adaptation [56]. Hsp90 has emerged as an essential trigger of an-
tifungal resistance to both azoles and echinocandins in C. albicans,
and this effect appears to result from the interaction with its client
protein calcineurin [57–59]. The crucial role of Hsp90 in basal
echinocandin resistance was also demonstrated in A. fumigatus
and A. terreus [57, 60, 61]. Its role in the caspofungin paradoxical
effect has been mainly described in A. fumigatus [61, 62].
While Hsp90 represents one of the most abundant cytosolic
protein under basal growth conditions, its expression increases
drastically under various stress conditions, such as heat shock
[63]. The cell wall stress induced by caspofungin results in an
approximately 2-fold increase of hsp90 transcript levels in A.
fumigatus [62] and is associated with a shift of Hsp90 from
the cytosol to the cell wall, septa, and sites of hyphal regener-
ation (Figure 1) [61], which supports its crucial role in this re-
sponse. This signiﬁcant increase of hsp90 expression seems to
be required for proper adaptive mechanisms in response to
caspofungin stress. Various genetic modiﬁcations of the A. fu-
migatus hsp90 promoter resulting in decreased hsp90 expres-
sion were associated with signiﬁcant hypersensitivity to
caspofungin and loss of the paradoxical effect at higher caspo-
fungin concentrations (4 µg/mL) [61, 62]. Pharmacologic inhi-
bition of Hsp90 by geldanamycin (GDA) resulted in a similar
effect [61].
Figure 1. Schematic model of calcineurin and heat shock protein 90 (Hsp90) network in response to caspofungin treatment. Caspofungin inhibits β-1,3-
glucan synthase (FksA). This cell wall stress is believed to trigger an increase in the expression of calcineurin. Calcineurin, a heterodimer comprising of the
catalytic subunit (CnaA) and the regulatory subunit (CnaB), is then activated in response to cell wall stress. Calcineurin function is inhibited by the binding of
the immunophilin-immunosuppressant complex (FK506-FKBP12). CnaA is activated through phosphorylation at 4 serine residues in the serine-proline rich
region (SPRR) and also at 2 serine residues in the C-terminus, as well as 2 serine residues in the N-terminus of CnaB. The phosphorylated [P] calcineurin
complex may bind to the phosphorylated transcription factor, CrzA, and dephosphorylate it, resulting in its nuclear translocation to mediate the transcription
of other genes. It is not known if caspofungin directly inﬂuences the phosphorylation status of calcineurin or CrzA. Calcineurin also orchestrates its function
through interaction with Hsp90, which is a target of geldanamycin (GDA). The activated calcineurin-Hsp90 complex is involved in the regulation of stress
response, cell wall integrity, growth, and drug resistance. Hsp90 responds to cell wall stress through an increase in its expression and by localizing to the
sites of cell wall damage. Lysine deacetylases (KDAC) control the acetylation status (Ac) and function of Hsp90. FK506, GDA, and trichostatin A (TSA)
represent different ways to interfere with this compensatory response and to potentiate the action of caspofungin. Known and putative interactions are
represented by solid and dotted single arrows, respectively. White arrows represent a change of localization. Black and bold arrows indicate increased
expression of hsp90.
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We have also shown that the 100-bp proximal region of the
A. fumigatus hsp90 promoter (p100) was crucial for basal resis-
tance to caspofungin including the paradoxical response [62].
Interestingly, the hsp90 promoter of C. albicans does not
seem to contain a sequence similar to A. fumigatus p100 and
was not able to restore the paradoxical response in A. fumigatus
lacking the p100 promoter region. These observations support
the existence of divergences in compensatory responses to cas-
pofungin-induced cell wall stress among fungi, as illustrated by
the species-speciﬁc characteristics of the paradoxical effect.
Hsp90 activation at the posttranslational level is also crucial
for triggering the cascade of Hsp90-dependent pathways of
echinocandin resistance in A. fumigatus. Although phosphory-
lation is an important process in governing Hsp90 function in
eukaryotes [64], mechanisms of acetylation and deacetylation
appear to be predominant in this case. Two acetylation sites
that are crucial for Hsp90 function have been identiﬁed in
fungi: K27 and K270 (Saccharomyces cerevisiae)/K271 (A. fumi-
gatus) [65, 66]. A deletion or acetylation-mimetic mutation of
K27 in A. fumigatus resulted in decreased basal resistance to
caspofungin and abolition of the paradoxical effect, which
could be restored by a deacetylation-mimetic mutation [66]. Al-
though the single mutation of K271 had no phenotypic impact,
the acetylation-mimetic mutation of both K27 and K271 result-
ed in further loss of thermal adaptation, as well as a growth de-
fect and decreased virulence similar to Hsp90 repression. A
comparable effect was achieved with trichostatin A, a broad-
spectrum inhibitor of both class I and II lysine deacetylases
(KDAC), which was shown to induce Hsp90 acetylation in eu-
karyotes [66, 67]. These results support the role of KDAC in
governing Hsp90 function in echinocandin resistance pathways.
Hsp90, working in concert with calcineurin, is another essen-
tial trigger of caspofungin basal resistance in A. fumigatus, and
its function in this pathway can be compromised by various
means. Impaired hsp90 expression at the transcriptional level,
direct inhibition of Hsp90 by competitive binding of GDA to
the ATPase pocket, and induction of Hsp90 acetylation by the
KDAC inhibitor trichostatin A (TSA) all result in increased sus-
ceptibility to caspofungin and abolition of the paradoxical ef-
fect. Both GDA and TSA demonstrated in vitro synergism
with caspofungin against A. fumigatus, and positive interactions
have also been observed in other Aspergillus species [66, 68].
PARADOXICAL EFFECT SUMMARY
From all previous published studies, the paradoxical effect ap-
pears to not be a true resistance mechanism, but rather a phe-
nomenon of dose-dependent tolerance in response to cell wall
stress and damage. This microbiological effect occurs much
more commonly with caspofungin than with the other 2 avail-
able echinocandins, and the effect has been documented in vitro
at concentrations that are achievable in human sera with con-
ventional dosing strategies, and potentially more relevant in
higher dosing schemes. While it is very clear that the paradox-
ical effect is a cell stress response, the exact molecular mecha-
nisms of this have not been completely deciphered. This
serves as an effective tool to study, in great detail, the complex
cellular actions and responses following antifungal drug expo-
sure in an effort to optimize our therapies and develop new
strategies for treatment.
What is unclear is the potential clinical relevance of this effect.
In vitro studies are clear that it reliably exists in a certain percent-
age of fungal strains, and in vivo studies are somewhat contradic-
tory in that some show no effect and others have reasonable
suggestions of decreased efﬁcacy using higher echinocandin dos-
ing. The few clinical studies that have even tangentially addressed
this issue are also not deﬁnitive. As larger daily or once-weekly
doses of echinocandins will lead to super-therapeutic concentra-
tions in the serum and infected tissues, this issue needs to con-
tinue to be explored to both deﬁne speciﬁc mechanisms of action
as well as optimally deliver life-saving antifungal agents.
Notes
Supplement sponsorship. This article appears as part of the supplement
“Advances and New Directions for Echinocandins,” sponsored by Astellas
Pharma Global Development, Inc.
Potential conﬂicts of interest. W. J. S. has received grants from Astellas
Pharma. All other authors report no potential conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines
for the management of candidiasis: 2009 update by the Infectious Dis-
eases Society of America. Clin Infect Dis 2009; 48:503–35.
2. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis:
clinical practice guidelines of the Infectious Diseases Society of Amer-
ica. Clin Infect Dis 2008; 46:327–60.
3. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in
vitro as a function of its concentration, and its paradoxically reduced
activity at high concentrations against certain organisms. J Exp Med
1948; 88:99–131.
4. Hall GS, Myles C, Pratt KJ, Washington JA. Cilofungin (LY121019), an
antifungal agent with speciﬁc activity against Candida albicans and
Candida tropicalis. Antimicrob Agents Chemother 1988; 32:1331–5.
5. Pfaller MA, Wey S, Gerarden T, Houston A, Wenzel RP. Susceptibility
of nosocomial isolates of Candida species to LY121019 and other anti-
fungal agents. Diagn Microbiol Infect Dis 1989; 12:1–4.
6. Bartizal C, Odds FC. Inﬂuences of methodological variables on suscept-
ibility testing of caspofungin against Candida species and Aspergillus fu-
migatus. Antimicrob Agents Chemother 2003; 47:2100–7.
7. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL.
In vitro pharmacodynamic properties of three antifungal agents against
preformed Candida albicans bioﬁlms determined by time-kill studies.
Antimicrob Agents Chemother 2002; 46:3634–6.
8. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin:
reduced activity against Candida albicans at high drug concentrations.
Antimicrob Agents Chemother 2004; 48:3407–11.
Effects of High-Dose Echinocandins • CID 2015:61 (Suppl 6) • S675
9. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the par-
adoxical effect of caspofungin at high drug concentrations. Diagn Mi-
crobiol Infect Dis 2005; 51:173–8.
10. Shields RK, Nguyen MH, Press EG, Clancy CJ. Five-minute exposure to
caspofungin results in prolonged postantifungal effects and eliminates
the paradoxical growth of Candida albicans. Antimicrob Agents Che-
mother 2011; 55:3598–602.
11. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth ef-
fect of caspofungin observed on bioﬁlms and planktonic cells of ﬁve dif-
ferent Candida species. Antimicrob Agents Chemother 2007; 51:
3081–8.
12. Walraven CJ, Bernardo SM, Wiederhold NP, Lee SA. Paradoxical anti-
fungal activity and structural observations in bioﬁlms formed by echi-
nocandin-resistant Candida albicans clinical isolates. Med Mycol 2014;
52:131–9.
13. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Compar-
ative in vitro pharmacodynamics of caspofungin, micafungin, and ani-
dulafungin against germinated and nongerminated Aspergillus conidia.
Antimicrob Agents Chemother 2008; 52:321–8.
14. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida
from caspofungin inhibition at concentrations above the MIC (para-
doxical effect) accomplished by increased cell wall chitin; evidence for
beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob
Agents Chemother 2006; 50:3160–1.
15. Bizerra FC, Melo AS, Katchburian E, et al. Changes in cell wall synthesis
and ultrastructure during paradoxical growth effect of caspofungin on
four different Candida species. Antimicrob Agents Chemother 2011;
55:302–10.
16. Rueda C, Cuenca-Estrella M, Zaragoza O. Paradoxical growth of Can-
dida albicans in the presence of caspofungin is associated with multiple
cell wall rearrangements and decreased virulence. Antimicrob Agents
Chemother 2014; 58:1071–83.
17. Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ. Paradox-
ical effect of caspofungin against Candida bloodstream isolates is medi-
ated by multiple pathways but eliminated in human serum. Antimicrob
Agents Chemother 2011; 55:2641–7.
18. Lee KK, Maccallum DM, Jacobsen MD, et al. Elevated cell wall chitin in
Candida albicans confers echinocandin resistance in vivo. Antimicrob
Agents Chemother 2012; 56:208–17.
19. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow
NA. Stimulation of chitin synthesis rescues Candida albicans from echi-
nocandins. PLoS Pathog 2008; 4:e1000040.
20. Szilagyi J, Foldi R, Bayegan S, Kardos G, Majoros L. Effect of nikkomy-
cin Z and 50% human serum on the killing activity of high-concentra-
tion caspofungin against Candida species using time-kill methodology.
J Chemother 2012; 24:18–25.
21. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of
echinocandins across Candida species in vitro: evidence for echinocan-
din-speciﬁc and Candida species-related differences. Antimicrob
Agents Chemother 2007; 51:2257–9.
22. Fleischhacker M, Radecke C, Schulz B, Ruhnke M. Paradoxical growth
effects of the echinocandins caspofungin and micafungin, but not of
anidulafungin, on clinical isolates of Candida albicans and C. dublinien-
sis. Eur J Clin Microbiol Infect Dis 2008; 27:127–31.
23. Khlif M, Bogreau H, Michel-Nguyen A, Ayadi A, Ranque S. Trailing or
paradoxical growth of Candida albicanswhen exposed to caspofungin is
not associated with microsatellite genotypes. Antimicrob Agents Che-
mother 2010; 54:1365–8.
24. Hadrich I, Neji S, Makni F, Ayadi A, Elloumi M, Ranque S. Trailing or
paradoxical growth of Aspergillus ﬂavus exposed to caspofungin is inde-
pendent of genotype. J Med Microbiol 2014; 63:1584–9.
25. Clemons KV, EspirituM, Parmar R, Stevens DA. Assessment of the par-
adoxical effect of caspofungin in therapy of candidiasis. Antimicrob
Agents Chemother 2006; 50:1293–7.
26. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin
antifungal MK-0991 (L-743,872): efﬁcacies in mouse models of
disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob
Agents Chemother 1997; 41:2333–8.
27. Graybill JR, Bocanegra R, Luther M, Fothergill A, Rinaldi MJ. Treatment
of murine Candida krusei or Candida glabrata infection with L-743,872.
Antimicrob Agents Chemother 1997; 41:1937–9.
28. Zanette RA, Kontoyiannis DP. Paradoxical effect to caspofungin in
Candida species does not confer survival advantage in a Drosophila
model of candidiasis. Virulence 2013; 4:497–8.
29. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efﬁcacy of caspo-
fungin (MK-0991) in experimental pulmonary aspegillosis in persis-
tently neutropenic rabbits: pharmacokinetics, drug deposition, and
relationship to galactomannan antigenemia. Antimicrob Agents Che-
mother 2002; 46:12–23.
30. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-
dependent activity and paradoxical effect of caspofungin and micafun-
gin in a neutropenic murine model of invasive pulmonary aspergillosis.
J Antimicrob Chemother 2008; 61:1140–4.
31. Moretti S, Bozza S, D’Angelo C, et al. Role of innate immune receptors
in paradoxical caspofungin activity in vivo in preclinical aspergillosis.
Antimicrob Agents Chemother 2012; 56:4268–76.
32. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis
RE. Pharmacodynamics of caspofungin in a murine model of invasive
pulmonary aspergillosis: evidence of concentration-dependent activity.
J Infect Dis 2004; 190:1464–71.
33. Gumbo T, Drusano GL, Liu W, et al. Once-weekly micafungin therapy is
as effective as daily therapy for disseminated candidiasis in mice with per-
sistent neutropenia. Antimicrob Agents Chemother 2007; 51:968–74.
34. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhi-
zopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain mea-
sured by quantitative PCR, and improves survival at a low but not a high
dose during murine disseminated zygomycosis. Antimicrob Agents
Chemother 2005; 49:721–7.
35. Betts RF, Nucci M, Talwar D, et al. A multicenter, double-blind trial of a
high-dose caspofungin treatment regimen versus a standard caspofun-
gin treatment regimen for adult patients with invasive candidiasis. Clin
Infect Dis 2009; 48:1676–84.
36. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin
for treatment of candidemia and other forms of invasive candidiasis.
Clin Infect Dis 2007; 45:883–93.
37. Safdar A, Rodriguez G, Rolston KV, et al. High-dose caspofungin com-
bination antifungal therapy in patients with hematologic malignancies
and hematopoietic stem cell transplantation. Bone Marrow Transplant
2007; 39:157–64.
38. Safdar A, Rodriguez G, Zuniga J, Akhrass FA, Pande A. High-dose
caspofungin as a component of combination antifungal therapy in 91
patients with neoplastic diseases and hematopoietic stem cell transplan-
tation: a critical review of short-term and long-term adverse events.
J Pharm Pract 2015; 28:175–82.
39. Yamazaki S, Nakamura F, Yoshimi A, Ichikawa M, Nannya Y, Kuroka-
wa M. Safety of high-dose micafungin for patients with hematological
diseases. Leuk Lymphoma 2014; 55:2572–6.
40. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of
the activity of caspofungin at high concentrations against Candida albi-
cans: possible role of cell wall integrity and calcineurin pathways. Anti-
microb Agents Chemother 2005; 49:5146–8.
41. Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Per-
fect JR. In vitro interactions between antifungals and immunosuppres-
sants against Aspergillus fumigatus. Antimicrob Agents Chemother
2004; 48:1664–9.
42. Steinbach WJ, Singh N, Miller JL, et al. In vitro interactions between
antifungals and immunosuppressants against Aspergillus fumigatus iso-
lates from transplant and nontransplant patients. Antimicrob Agents
Chemother 2004; 48:4922–5.
43. SteinbachWJ, Cramer RA Jr, Perfect BZ, et al. Calcineurin inhibition or
mutation enhances cell wall inhibitors against Aspergillus fumigatus.
Antimicrobial Agents Chemother 2007; 51:2979–81.
S676 • CID 2015:61 (Suppl 6) • Steinbach et al
44. Steinbach WJ, Cramer RA Jr, Perfect BZ, et al. Calcineurin controls
growth, morphology, and pathogenicity in Aspergillus fumigatus.
Eukaryotic Cell 2006; 5:1091–103.
45. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J. Harness-
ing calcineurin as a novel anti-infective agent against invasive fungal
infections. Nat Rev Microbiol 2007; 5:418–30.
46. Cramer RA Jr, Perfect BZ, Pinchai N, et al. Calcineurin target CrzA
regulates conidial germination, hyphal growth, and pathogenesis of
Aspergillus fumigatus. Eukaryotic Cell 2008; 7:1085–97.
47. Fortwendel JR, Juvvadi PR, Pinchai N, et al. Differential effects of inhib-
iting chitin and 1,3-beta-D-glucan synthesis in Ras and calcineurin mu-
tants of Aspergillus fumigatus. Antimicrob Agents Chemother 2009;
53:476–82.
48. Fortwendel JR, Juvvadi PR, Perfect BZ, Rogg LE, Perfect JR, Steinbach
WJ. Transcriptional regulation of chitin synthases by calcineurin con-
trols paradoxical growth of Aspergillus fumigatus in response to caspo-
fungin. Antimicrobial Agents Chemother 2010; 54:1555–63.
49. Rogg LE, Fortwendel JR, Juvvadi PR, Lilley A, Steinbach WJ. The chitin
synthase genes chsA and chsC are not required for cell wall stress re-
sponses in the human pathogen Aspergillus fumigatus. Biochem Bio-
phys Res Commun 2011; 411:549–54.
50. Muszkieta L, Aimanianda V, Mellado E, et al. Deciphering the role of
the chitin synthase families 1 and 2 in the in vivo and in vitro growth of
Aspergillus fumigatus by multiple gene targeting deletion. Cell Micro-
biol 2014; 16:1784–805.
51. Juvvadi PR, Lamoth F, SteinbachWJ. Calcineurin as a multifunctional reg-
ulator: unraveling novel functions in fungal stress responses, hyphal
growth, drug resistance, and pathogenesis. Fungal Biol Rev 2014; 28:56–69.
52. Juvvadi PR, Fortwendel JR, Rogg LE, Burns KA, Randell SH, Steinbach
WJ. Localization and activity of the calcineurin catalytic and regulatory
subunit complex at the septum is essential for hyphal elongation and prop-
er septation in Aspergillus fumigatus. Mol Microbiol 2011; 82:1235–59.
53. Juvvadi PR, Gehrke C, Fortwendel JR, et al. Phosphorylation of calci-
neurin at a novel serine-proline rich region orchestrates hyphal growth
and virulence in Aspergillus fumigatus. PLoS Pathog 2013; 9:e1003564.
54. Suresh K, Subramanyam C. A putative role for calmodulin in the acti-
vation of Neurospora crassa chitin synthase. FEMS Microbiol Lett 1997;
150:95–100.
55. Deshpande MV, O’Donnell R, Gooday GW. Regulation of chitin syn-
thase activity in the dimorphic fungus Benjaminiella poitrasii by exter-
nal osmotic pressure. FEMS Microbiol Lett 1997; 152:327–32.
56. Leach MD, Klipp E, Cowen LE, Brown AJ. Fungal Hsp90: a biological
transistor that tunes cellular outputs to thermal inputs. Nat Rev Micro-
biol 2012; 10:693–704.
57. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new
traits: drug resistance in diverse fungi. Science 2005; 309:2185–9.
58. Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S.
Genetic architecture of Hsp90-dependent drug resistance. Eukaryot
Cell 2006; 5:2184–8.
59. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE.
Hsp90 governs echinocandin resistance in the pathogenic yeast Candi-
da albicans via calcineurin. PLoS Pathog 2009; 5:e1000532.
60. Cowen LE, Singh SD, Köhler JR, et al. Harnessing Hsp90 function as a
powerful, broadly effective therapeutic strategy for fungal infectious dis-
ease. Proc Natl Acad Sci U S A 2009; 106:2818–23.
61. Lamoth F, Juvvadi PR, Fortwendel JR, SteinbachWJ. Heat shock protein
90 is required for conidiation and cell wall integrity in Aspergillus fumi-
gatus. Eukaryot Cell 2012; 11:1324–32.
62. Lamoth F, Juvvadi PR, Gehrke C, Asfaw YG, Steinbach WJ. Transcrip-
tional activation of heat shock protein 90 mediated via a proximal pro-
moter region as trigger of caspofungin resistance in Aspergillus
fumigatus. J Infect Dis 2014; 209:473–81.
63. Lamoth F, Juvvadi PR, Steinbach WJ. Heat shock protein 90 (Hsp90): a
novel antifungal target against Aspergillus fumigatus. Crit Rev Microbiol
2014; 22:1–12.
64. Mollapour M, Neckers L. Post-translational modiﬁcations of Hsp90 and
their contributions to chaperone regulation. Biochim Biophys Acta
2012; 1823:648–55.
65. Robbins N, Leach MD, Cowen LE. Lysine deacetylases Hda1 and Rpd3
regulate Hsp90 function thereby governing fungal drug resistance. Cell
Rep 2012; 2:878–88.
66. Lamoth F, Juvvadi PR, Soderblom EJ, Moseley MA, Asfaw YG, Stein-
bach WJ. Identiﬁcation of a key lysine residue in heat shock protein
90 required for azole and echinocandin resistance in Aspergillus fumi-
gatus. Antimicrob Agents Chemother 2014; 58:1889–96.
67. Scroggins BT, Robzyk K, Wang D, et al. An acetylation site in the middle
domain of Hsp90 regulates chaperone function. Mol Cell 2007;
25:151–9.
68. Lamoth F, Juvvadi PR, Gehrke C, Steinbach WJ. In vitro activity of
calcineurin and heat shock protein 90 inhibitors against Aspergillus
fumigatus azole- and echinocandin-resistant strains. Antimicrob Agents
Chemother 2013; 57:1035–9.
Effects of High-Dose Echinocandins • CID 2015:61 (Suppl 6) • S677
